Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$17.23
+0.4%
$15.76
$13.09
$18.92
$6.13B0.56381,714 shs492,548 shs
Liquidia Corporation stock logo
LQDA
Liquidia
$78.93
$60.77
$11.86
$80.69
$7.02B0.552.57 million shs1.41 million shs
NovoCure Limited stock logo
NVCR
NovoCure
$17.20
$16.30
$9.82
$18.92
$1.99B0.941.69 million shs1.95 million shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€18.98
-0.1%
€17.75
€12.89
€28.00
€5.75B0.78384,750 shs337,500 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%+5.76%+12.07%+4.51%+25.23%
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+0.97%+26.64%+109.47%+554.48%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%+11.47%-4.39%+63.03%-3.80%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.00%+6.74%+2.12%+38.36%-22.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$17.23
+0.4%
$15.76
$13.09
$18.92
$6.13B0.56381,714 shs492,548 shs
Liquidia Corporation stock logo
LQDA
Liquidia
$78.93
$60.77
$11.86
$80.69
$7.02B0.552.57 million shs1.41 million shs
NovoCure Limited stock logo
NVCR
NovoCure
$17.20
$16.30
$9.82
$18.92
$1.99B0.941.69 million shs1.95 million shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€18.98
-0.1%
€17.75
€12.89
€28.00
€5.75B0.78384,750 shs337,500 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%+5.76%+12.07%+4.51%+25.23%
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+0.97%+26.64%+109.47%+554.48%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%+11.47%-4.39%+63.03%-3.80%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.00%+6.74%+2.12%+38.36%-22.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.21
Hold$17.923.97% Upside
Liquidia Corporation stock logo
LQDA
Liquidia
2.82
Moderate Buy$68.88-12.74% Downside
NovoCure Limited stock logo
NVCR
NovoCure
2.29
Hold$25.6749.22% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.83
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest NVCR, BLCO, STVN, and LQDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
DowngradeHold (C-)Sell (D+)
6/29/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Reiterated RatingBuyNeutral$64.00 ➝ $79.00
6/22/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$59.00 ➝ $109.00
6/18/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
UpgradeSell (D+)Hold (C-)
6/18/2026
NovoCure Limited stock logo
NVCR
NovoCure
Reiterated RatingBuy$48.00 ➝ $46.00
6/17/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
UpgradeStrong-Buy
6/16/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
Initiated CoverageBuy$25.00
6/8/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
Reiterated RatingSell (D+)
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$67.00 ➝ $75.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price Target$75.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price Target$28.00
(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.21$1.68 per share10.28$18.40 per share0.94
Liquidia Corporation stock logo
LQDA
Liquidia
$288.07M24.37N/AN/A$0.51 per share154.76
NovoCure Limited stock logo
NVCR
NovoCure
$674.41M2.95N/AN/A$3.04 per share5.66
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.34B4.28€0.88 per share21.54€5.55 per share3.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.62N/A16.100.53-4.21%3.60%1.69%7/29/2026 (Estimated)
Liquidia Corporation stock logo
LQDA
Liquidia
-$68.92M$0.14563.8316.04N/A7.74%46.82%7.06%8/11/2026 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$136.23M-$1.53N/AN/AN/A-25.66%-50.82%-16.48%7/23/2026 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€158.21M€0.5932.1823.731.7511.76%10.27%6.08%N/A

Latest NVCR, BLCO, STVN, and LQDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2026Q2 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.16N/AN/AN/A$1.37 billionN/A
7/23/2026Q2 2026
NovoCure Limited stock logo
NVCR
NovoCure
-$0.30N/AN/AN/A$172.72 millionN/A
5/11/2026Q1 2026
Liquidia Corporation stock logo
LQDA
Liquidia
$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million
5/8/2026Q1 2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.12€0.11-€0.01€0.10N/A€273.57 million
4/30/2026Q1 2026
NovoCure Limited stock logo
NVCR
NovoCure
-$0.5122-$0.62-$0.1078-$0.62$167.77 million$174.06 million
4/29/2026Q1 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Liquidia Corporation stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years

Latest NVCR, BLCO, STVN, and LQDA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/10/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
annual€0.050.31%6/11/20266/11/20267/29/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.78
1.53
0.99
Liquidia Corporation stock logo
LQDA
Liquidia
1.18
2.22
2.03
NovoCure Limited stock logo
NVCR
NovoCure
0.71
2.90
2.70
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.21
1.63
1.11

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Liquidia Corporation stock logo
LQDA
Liquidia
64.54%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
Liquidia Corporation stock logo
LQDA
Liquidia
25.60%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000357.04 million351.87 millionOptionable
Liquidia Corporation stock logo
LQDA
Liquidia
5088.93 million66.16 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,605115.82 million109.43 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
6,010302.84 million300.72 millionOptionable

Recent News About These Companies

TD Cowen Initiates a Buy Rating on Stevanato Group (STVN)
STVN Share News Today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$17.23 +0.07 (+0.42%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$17.14 -0.09 (-0.50%)
As of 07/2/2026 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Liquidia stock logo

Liquidia NASDAQ:LQDA

$78.93 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$78.84 -0.09 (-0.12%)
As of 07/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$17.20 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$17.08 -0.12 (-0.70%)
As of 07/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€18.98 -0.02 (-0.08%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
€19.01 +0.03 (+0.14%)
As of 07/2/2026 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.